RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Sirnaomics of Maryland was approved to start US trials of its anti-cancer/anti-fibrosis siRNA (small interfering RNA) therapeutic in patients with advanced cholangiocarcinoma (CCA). Sirnaomics has facilities in Suzhou and Guangzhou. STP705 works by silencing both TGF-β1 and COX-2 gene expression within the liver. CCA is the second most common hepatic primary malignancy and more common in Asia than the west. It is also known as bile duct adenocarcinoma and biliary tract cancer. Five-year survival ranges from 2-30%.
Source: China Biotoday
